Prognostic Role of HERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Sep 23

PMID 36142530

Authors

Jessica Iorio

Lorenzo Antonuzzo

Emanuela Scarpi

Massimo DAmico

Claudia Duranti

Luca Messerini

Clotilde Sparano

Damiano Caputo

Daniele Lavacchi

Domenico Borzomati

Alice Antonelli

Lorenzo Nibid

Giuseppe Perrone

Alessandro Coppola

Roberto Coppola

Francesco Di Costanzo

Elena Lastraioli

Annarosa Arcangeli

Affiliations

Soon will be listed here.

Abstract

hERG1 potassium channels are widely expressed in human cancers of different origins, where they affect several key aspects of cellular behaviour. The present study was designed to evaluate the expression and clinical relevance of hERG1 protein in cancer tissues from patients suffering from neuroendocrine tumours (NETs) of ileal (iNETs) and pancreatic (pNETs) origin, with available clinicopathological history and follow-up. The study was carried out by immunohistochemistry with an anti-hERG1 monoclonal antibody. In a subset of samples, a different antibody directed against the hERG1/β1 integrin complex was also used. The analysis showed for the first time that hERG1 is expressed in human NETs originating from either the ileum or the pancreas. hERG1 turned out to have a prognostic value in NETs, showing (i) a statistically significant positive impact on OS of patients affected by ileal NETs, regardless the TNM stage; (ii) a statistically significant positive impact on OS of patients affected by aggressive (TNM stage IV) disease, either ileal or pancreatic; (iii) a trend to a negative impact on OS of patients affected by less aggressive (TNM stage I-III) disease, either ileal or pancreatic. Moreover, in order to evaluate whether ERG1 was functionally expressed in a cellular model of pNET, the INS1E rat insulinoma cell line was used, and it emerged that blocking ERG1 with a specific inhibitor of the channel (E4031) turned out in a significant reduction in cell proliferation.

Citing Articles

Ion channels in lung cancer: biological and clinical relevance.

Capitani C, Chioccioli Altadonna G, Santillo M, Lastraioli E Front Pharmacol. 2023; 14:1283623.

PMID: 37942486 PMC: 10627838. DOI: 10.3389/fphar.2023.1283623.

Integrins regulate hERG1 dynamics by girdin-dependent Gαi3: signaling and modeling in cancer cells.

Duranti C, Iorio J, Bagni G, Chioccioli Altadonna G, Fillion T, Lulli M Life Sci Alliance. 2023; 7(1).

PMID: 37923359 PMC: 10624597. DOI: 10.26508/lsa.202302135.

Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma.

Lottini T, Duranti C, Iorio J, Martinelli M, Colasurdo R, DAlessandro F Cancers (Basel). 2023; 15(7).

PMID: 37046674 PMC: 10093586. DOI: 10.3390/cancers15072013.

References

Cherubini A, Taddei G, Crociani O, Paglierani M, Buccoliero A, Fontana L . HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer. 2000; 83(12):1722-9. PMC: 2363441. DOI: 10.1054/bjoc.2000.1497. View

Binggeli R, Weinstein R . Membrane potentials and sodium channels: hypotheses for growth regulation and cancer formation based on changes in sodium channels and gap junctions. J Theor Biol. 1986; 123(4):377-401. DOI: 10.1016/s0022-5193(86)80209-0. View

Lottini T, Iorio J, Lastraioli E, Carraresi L, Duranti C, Sala C . Transgenic mice overexpressing the LH receptor in the female reproductive system spontaneously develop endometrial tumour masses. Sci Rep. 2021; 11(1):8847. PMC: 8065064. DOI: 10.1038/s41598-021-87492-5. View

Bauer C, Schafer R, Schiemann D, Reid G, Hanganu I, Schwarz J . A functional role of the erg-like inward-rectifying K+ current in prolactin secretion from rat lactotrophs. Mol Cell Endocrinol. 1999; 148(1-2):37-45. DOI: 10.1016/s0303-7207(98)00241-x. View

Huang X, Jan L . Targeting potassium channels in cancer. J Cell Biol. 2014; 206(2):151-62. PMC: 4107787. DOI: 10.1083/jcb.201404136. View

Lastraioli E, Bencini L, Bianchini E, Romoli M, Crociani O, Giommoni E . hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. Transl Oncol. 2012; 5(2):105-12. PMC: 3323932. DOI: 10.1593/tlo.11250. View

Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F . Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel). 2019; 11(8). PMC: 6721814. DOI: 10.3390/cancers11081113. View

Arcangeli A, Becchetti A, Mannini A, Mugnai G, De Filippi P, Tarone G . Integrin-mediated neurite outgrowth in neuroblastoma cells depends on the activation of potassium channels. J Cell Biol. 1993; 122(5):1131-43. PMC: 2119629. DOI: 10.1083/jcb.122.5.1131. View

Pillozzi S, Brizzi M, Bernabei P, Bartolozzi B, Caporale R, Basile V . VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007; 110(4):1238-50. DOI: 10.1182/blood-2006-02-003772. View

10.

Duranti C, Lastraioli E, Iorio J, Capitani C, Carraresi L, Gonnelli L . Expression and purification of a novel single-chain diabody (scDb-hERG1/β1) from Pichia pastoris transformants. Protein Expr Purif. 2021; 184:105879. DOI: 10.1016/j.pep.2021.105879. View

11.

Muratori L, Petroni G, Antonuzzo L, Boni L, Iorio J, Lastraioli E . hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. Onco Targets Ther. 2016; 9:6325-6332. PMC: 5072508. DOI: 10.2147/OTT.S114090. View

12.

Lastraioli E, Lottini T, Iorio J, Freschi G, Fazi M, Duranti C . hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance. Oncotarget. 2016; 7(37):59535-59547. PMC: 5312329. DOI: 10.18632/oncotarget.11149. View

13.

Fiorio Pla A, Gkika D . Ca2+ Channel Toolkit in Neuroendocrine Tumors. Neuroendocrinology. 2019; 110(1-2):147-154. DOI: 10.1159/000501397. View

14.

Oronsky B, Ma P, Morgensztern D, Carter C . Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017; 19(12):991-1002. PMC: 5678742. DOI: 10.1016/j.neo.2017.09.002. View

15.

Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, Manoli S . hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Br J Cancer. 2015; 112(6):1076-87. PMC: 4366888. DOI: 10.1038/bjc.2015.28. View

16.

Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H . herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 2004; 64(2):606-11. DOI: 10.1158/0008-5472.can-03-2360. View

17.

Becchetti A, Duranti C, Arcangeli A . Dynamics and physiological meaning of complexes between ion channels and integrin receptors: the case of Kv11.1. Am J Physiol Cell Physiol. 2022; 322(6):C1138-C1150. DOI: 10.1152/ajpcell.00107.2022. View

18.

Duranti C, Iorio J, Lottini T, Lastraioli E, Crescioli S, Bagni G . Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers. Mol Cancer Ther. 2021; 20(8):1338-1349. DOI: 10.1158/1535-7163.MCT-20-1111. View

19.

Iorio J, Lastraioli E, Tofani L, Petroni G, Antonuzzo L, Messerini L . hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients. Transl Oncol. 2020; 13(3):100740. PMC: 7044526. DOI: 10.1016/j.tranon.2020.01.001. View

20.

Modlin I, Bodei L, Kidd M . Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016; 30(1):59-77. DOI: 10.1016/j.beem.2016.01.002. View